Results 221 to 230 of about 141,949 (308)

Neutrophil extracellular traps induced by activated platelets as a cause of neutrophil–platelet aggregation in β‐thalassaemia/haemoglobin E patients

open access: yesBritish Journal of Haematology, EarlyView.
Abnormal neutrophils and platelets in splenectomised β‐thalassaemia/haemoglobin E (HbE) disease contribute to neutrophil–platelet aggregation, leading to a high risk of thrombus formation. Activated platelets induce neutrophils to generate neutrophil extracellular trap (NETs) via the P‐selectin–P‐selectin glycoprotein ligand‐1 (PSGL1) pathway, which ...
Rattanawan Thubthed   +11 more
wiley   +1 more source

From variant detection to interpretation in idiopathic erythrocytosis: A structured approach applied to a clinical cohort

open access: yesBritish Journal of Haematology, EarlyView.
Targeted next‐generation sequencing combined with a structured interpretative framework integrating gene–disease validity, population data, computational predictions, ACMG criteria and structural modelling enabled prioritisation of rare variants in idiopathic erythrocytosis, highlighting the genetic heterogeneity and biological complexity underlying ...
Alessandra Giannella   +21 more
wiley   +1 more source

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source

Haemostatic changes and bleeding with anti‐IL‐6 directed therapy in autoimmune diseases

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Anti‐IL‐6 directed therapy, especially tocilizumab (TCZ), is widely used for the treatment of autoimmune diseases such as rheumatoid arthritis, giant cell arteritis and systemic juvenile idiopathic arthritis. Next to being a master regulator of inflammation, IL‐6 also is an important regulator of haemostasis. Although generally well tolerated,
Charlotte D. C. C. van der Heijden   +3 more
wiley   +1 more source

Physiological Basis of Sex Differences in Human Performance and Exercise‐Associated Pathology

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT The presence of sex differences in human physical performance is well‐established and shaped by distinct endocrine, anatomical and physiological mechanisms. Despite sustained advances, our understanding of how inherent biological factors drive variations in exercise capacity and related pathologies is still developing.
David A. Holdsworth   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy